AccuMetab™ Human CYP26A1 Enzyme, Catalytically Active

CAT#: ITS-0426-YL29
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP26A1 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP26A1 is a highly specific hydroxylase that tightly regulates the cellular levels of retinoic acid during embryogenesis and adult tissue homeostasis. It is a vital regulatory screen in toxicology to predict the teratogenic potential of novel compounds and evaluate retinoid-based therapeutics.
Key Features
Specialized retinoic acid hydroxylase; Evaluates teratogenicity in dermatological drugs; Critical for modeling embryofetal toxicity; Supplied in controlled, low-reductase formats
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry